Surmodics, Inc. (NASDAQ:SRDX) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations And Financial Condition.
On November 8, 2017, Surmodics, Inc. (the “Company”) issued a press release (the “Press Release”) announcing the results for the quarter ended September 30, 2017.A copy of the full text of the Press Release is furnished as Exhibit 99.1 to this report.
The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
| Exhibit Number | Description |
| 99.1 | Press Release dated November 8, 2017. |
SURMODICS INC ExhibitEX-99.1 2 a51712735ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Surmodics Reports Fourth Quarter Fiscal 2017 Results and Provides Fiscal 2018 Guidance EDEN PRAIRIE,…To view the full exhibit click here
About Surmodics, Inc. (NASDAQ:SRDX)
Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.
